SecBot SecBot
8-K ·Filed May 11, 2026

BCAX

Bicara Therapeutics Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001628280-26-033135
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on ASCO 2026 data (May 29-June 2) and the Q3 2026 dosing study initiation, not on the quarterly loss. Monitor for interim analysis readout from FORTIFI-HN01 expected mid-2027. The $539.8M cash position removes near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.92
T+0 close · May 11, 2026 · via day close
Latest settled
+12.96%
T+60 · $25.89
Vs SPY
+8.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $22.92entry
  2. T+1 · 6mo ago −2.36%α −2.22% · $22.38
  3. T+5 · 6mo ago −15.84%α −15.75% · $19.29
  4. T+20 · 5mo ago −10.30%α −9.99% · $20.56
  5. T+60 · 3mo ago +12.96%α +8.57% · $25.89

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bicara Therapeutics reported Q1 2026 net loss of $56.2M ($-0.93/share), wider than the $-0.68 loss in Q1 2025, driven by increased R&D spend on the FORTIFI-HN01 pivotal trial. The company has $539.8M in cash, extended runway into H1 2029, and announced key clinical and executive milestones including a planned Q3 2026 randomized dosing study and ASCO 2026 data presentation. This is a pre-revenue clinical-stage biotech, the widening loss is expected and not a surprise; the stock will move on clinical catalysts, not quarterly financials.

Key Financial Metrics

EPS
−$0.93
Rating
in line

Key Facts

  • Net loss of $56.2M for Q1 2026 vs $36.8M in Q1 2025
  • Cash, cash equivalents and marketable securities of $539.8M as of March 31, 2026
  • Cash runway extended into first half of 2029
  • Plan to initiate randomized study of loading + Q3W maintenance dosing in Q3 2026
  • Long-term follow-up data from Phase 1b to be presented at ASCO 2026 (May 29-June 2)
  • Bill Schelman promoted to CMO; Chris Sarchi appointed as Chief Commercial Officer
  • R&D expenses $47.5M in Q1 2026 vs $34.3M in Q1 2025
  • Net loss per share $-0.93 vs $-0.68 in prior year period

Financial Impact

Net loss widened by $19.4M YoY to $56.2M; cash position $539.8M provides runway into H1 2029

net losscash positionR&D expenses

Risk Factors

  • Clinical trial failure or disappointing ASCO data
  • Dilution risk if additional financing needed before potential approval
  • Regulatory delays in dosing study or accelerated approval pathway

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-033135
Document: bcax-20260511.htm0001628280-26-033135
Document: 0001628280-26-033135-index-headers.html0001628280-26-033135
Document: 0001628280-26-033135-index.html0001628280-26-033135
Document: 0001628280-26-033135.txt0001628280-26-033135
8-K Data (Synthetic)0001628280-26-033135

Track record

26 reports on BCAX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
  2. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  3. Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  4. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
  5. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
  7. Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
  8. Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
  9. Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026